Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Pan, Yuesong ^a   Chen, Qidong ^a   Zhao, Xingquan ^a   Liao, Xiaoling ^a   Wang, Chunjuan ^a   Du, Wanliang ^a   Liu, Gaifen ^a   Liu, Liping ^a   Wang, Chunxue ^a   Wang, Yilong ^a   Wang, Yongjun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

AGED; BRAIN ISCHEMIA; CHINA; COST; ECONOMICS; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MALE; MIDDLE AGED; PROCEDURES; STROKE; TIME;

AGED; BRAIN ISCHEMIA; CHINA; COSTS AND COST ANALYSIS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84908181076     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110525     Document Type: Article

References (36)

1. Yang G, Wang Y, Zeng Y, Gao GF, Liang X, et al. (2013) Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 381: 1987-2015.
2. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, et al. (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274: 1017-1025.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581-1587.
4. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, et al. (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363: 768-774.
5. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, et al. (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359: 1317-1329.
6. Wahlgren N, Ahmed N, Dávalos A, Hacke W, Millán M, et al. (2008) Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 372: 1303-1309.
7. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, et al. (1998) Costeffectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 50: 883-890.
8. Sinclair SE, Frighetto L, Loewen PS, Sunderji R, Teal P, et al. (2001) Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 19: 927-936.
9. Sandercock P, Berge E, Dennis M, Forbes J, Hand P, et al. (2004) Costeffectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 35: 1490-1497.
10. Ehlers L, Andersen G, Clausen LB, Bech M, Kjølby M (2007) Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 38: 85-89.
11. Jung KT, Shin DW, Lee KJ, Oh M (2010) Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review. J Clin Neurol 6: 117-126.
12. Tung CE, Win SS, Lansberg MG (2011) Cost-effectiveness of tissue-type plasminogen activator in the 3-to 4.5-hour time window for acute ischemic stroke. Stroke 42: 2257-2262.
13. Kim AS, Nguyen-Huynh M, Johnston SC (2011) A cost-utility analysis of mechanical thrombectomy as an adjunct to intravenous tissue-type plasminogen activator for acute large-vessel ischemic stroke. Stroke 42: 2013-2018.
14. Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL (2012) A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med 61: 46-55.
15. Tan Tanny SP, Busija L, Liew D, Teo S, Davis SM, et al. (2013) Costeffectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center. Stroke 44: 2269-2274.
16. Kim AS, Johnston SC (2013) Temporal and geographic trends in the global stroke epidemic. Stroke 44: S123-S125.
17. Wang Y, Liao X, Zhao X, Wang DZ, Wang C, et al. (2011) Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke 42: 1658-1664.
18. Demaerschalk BM, Durocher DL (2007) How diagnosis-related group 559 will change the US Medicare cost reimbursement ratio for stroke centers. Stroke 38: 1309-1312.
19. Peltola M, Quentin W (2013) Diagnosis-related groups for stroke in Europe: patient classification and hospital reimbursement in 11 countries. Cerebrovasc Dis 35: 113-123.
20. Beijing Municipal Commission of Development and Reform. The maximum retail price of western medicine (in Chinese). Website: http://service2.bjpc.gov.cn/bjpc/mediprice/WesternMedicine-qry.jsp. Accessed 2013 July 28.
21. Liao XL, Wang CX, Wang YL, Wang CJ, Zhao XQ, et al. (2012) Thrombolysis Implementation and Monitor of acute ischemic Stroke in China (TIMS-China) Investigators. Implementation and outcome of thrombolysis with alteplase 3 to 4.5 h after acute stroke in Chinese patients. CNS Neurosci Ther 19: 43-47.
22. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276: 1253-1258.
23. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, et al. (2010) Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375: 1695-1703.
24. Wang Y, Cui L, Ji X, Dong Q, Zeng J, et al. (2011) The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke 6: 355-361.
25. National Bureau of Statistics of China. The 2010 Population Census of the Peaple's Republic of China (in Chinese). Website: http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.Htm. Accessed 2012 October 25.
26. Ministry of Health of the People's Republic of China (2012) China Health Statistics Yearbook 2012. Beijing: Peking Union Medical College Press (in Chinese).
27. Samsa GP, Reutter RA, Parmigiani G, Ancukiewicz M, Abrahamse P, et al. (1999) Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol 52: 259-271.
28. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, et al. (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349: 1019-1026.
29. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, et al. (2012) Costeffectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 110: 845-851.
30. You JH, Tsui KK, Wong RS, Cheng G (2012) Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS One 7: e39640.
31. Commission on Macroeconomics and Health of World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Websit: http://www.who.int/choice/costs/CER-thresholds/en/.Accessed 2012 October 17.
32. Heeley E, Anderson CS, Huang Y, Jan S, Li Y, et al. (2009) Role of health insurance in averting economic hardship in families after acute stroke in China. Stroke 40: 2149-2156.
33. Li A, Huang ZQ, Liu HT, Deng YT, Xiao JW, et al. (2009) Knowledge, attitude and behavior for stroke and rehabilitation in stroke patients and relatives. (in Chinese). Chin J Rehabil Theory and Pract 15: 252-254.
34. Gao YL, Chen LD, Tao J, Chen SM (2009) Investigation on the investment and popularization of rehabilitation from cerebral apoplexy: in 2 communities of Xiamen City. (in Chinese). Chin J Convalescent Med 18: 472-474.
35. Ma R, Wang C, Zhao X, Xu M, Lv Y, et al. (2008) A survey on compliance with secondary stroke prevention guidelines and follow up for the inpatients with atherosclerotic cerebral infarction/transient ischemic attack. Neurol Res 30: 383-388.
36. Wei JW, Wang JG, Huang Y, Liu M, Wu Y, et al. (2010) Secondary prevention of ischemic stroke in urban China. Stroke 41: 967-974.